Do analysts prefer SLGL or ZYBT?

Sol-Gel Technologies currently has a consensus price target of $197.50, suggesting a potential upside of 175.18%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SLGL or ZYBT?

Sol-Gel Technologies has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sol-Gel Technologies $19.39M 12.10 -$6.13M -$5.64 N/A Zhengye Biotechnology $116.36M 0.70 -$9.98M N/A N/A

Does the media refer more to SLGL or ZYBT?

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 6 mentions for Zhengye Biotechnology. Sol-Gel Technologies' average media sentiment score of 0.76 beat Zhengye Biotechnology's score of 0.67 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ANTX or ZYBT?

Anthem currently has a consensus target price of $9.00, suggesting a potential upside of 104.55%. Given Anthem's stronger consensus rating and higher probable upside, analysts clearly believe Anthem is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anthem 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ANTX or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Anthem. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Zhengye Biotechnology $116.36M 0.70 -$9.98M N/A N/A

Is ANTX or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Zhengye Biotechnology N/A N/A N/A

Do analysts rate ZYBT or ZNTL?

Zentalis Pharmaceuticals has a consensus price target of $7.50, indicating a potential upside of 184.09%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zentalis Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, ZYBT or ZNTL?

Zhengye Biotechnology has higher revenue and earnings than Zentalis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $116.36M 0.70 -$9.98M N/A N/A Zentalis Pharmaceuticals $67.43M 2.81 -$137.06M -$1.95 N/A

Is ZYBT or ZNTL more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Zentalis Pharmaceuticals N/A -70.18% -51.46%

Does the media favor ZYBT or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 6 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.67 beat Zentalis Pharmaceuticals' score of 0.33 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, CRDL or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Cardiol Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Zhengye Biotechnology $116.36M 0.70 -$9.98M N/A N/A

Is CRDL or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Zhengye Biotechnology N/A N/A N/A

Do analysts prefer ZYBT or ACOG?

Alpha Cognition has a consensus price target of $18.00, indicating a potential upside of 99.12%. Given Alpha Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Alpha Cognition is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better valuation & earnings, ZYBT or ACOG?

Zhengye Biotechnology has higher revenue and earnings than Alpha Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $116.36M 0.70 -$9.98M N/A N/A Alpha Cognition $15.26M 12.90 -$20.67M -$1.10 N/A

Does the media favor ZYBT or ACOG?

In the previous week, Zhengye Biotechnology had 1 more articles in the media than Alpha Cognition. MarketBeat recorded 6 mentions for Zhengye Biotechnology and 5 mentions for Alpha Cognition. Zhengye Biotechnology's average media sentiment score of 0.67 beat Alpha Cognition's score of 0.59 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zhengye Biotechnology (ZYBT) Competitors

$1.73 +0.58 (+50.45%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.79 +0.06 (+3.24%)

As of 10/9/2026 08:00 PM Eastern

Compare

ZYBT vs. SLGL, ANTX, ZNTL, CRDL, and ACOG

Should you buy Zhengye Biotechnology stock or one of its competitors? Zhengye Biotechnology's main competitors and comparable companies include Sol-Gel Technologies (SLGL), Anthem (ANTX), Zentalis Pharmaceuticals (ZNTL), Cardiol Therapeutics (CRDL), and Alpha Cognition (ACOG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zhengye Biotechnology compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 6 mentions for Zhengye Biotechnology. Sol-Gel Technologies' average media sentiment score of 0.76 beat Zhengye Biotechnology's score of 0.67 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zhengye Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.31, suggesting that its stock price is 331% less volatile than the broader market.

Zhengye Biotechnology has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Zhengye Biotechnology's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Zhengye Biotechnology	N/A	N/A	N/A

Sol-Gel Technologies has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.10	-$6.13M	-$5.64	N/A
Zhengye Biotechnology	$116.36M	0.70	-$9.98M	N/A	N/A

26.2% of Sol-Gel Technologies shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sol-Gel Technologies currently has a consensus price target of $197.50, suggesting a potential upside of 175.18%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sol-Gel Technologies beats Zhengye Biotechnology on 11 of the 15 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Anthem?

Anthem (NASDAQ:ANTX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

90.5% of Anthem shares are owned by institutional investors. 22.6% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Zhengye Biotechnology had 5 more articles in the media than Anthem. MarketBeat recorded 6 mentions for Zhengye Biotechnology and 1 mentions for Anthem. Zhengye Biotechnology's average media sentiment score of 0.67 beat Anthem's score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Anthem	Neutral
Zhengye Biotechnology	Positive

Anthem currently has a consensus target price of $9.00, suggesting a potential upside of 104.55%. Given Anthem's stronger consensus rating and higher probable upside, analysts clearly believe Anthem is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anthem has a beta of -0.98, suggesting that its stock price is 198% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.31, suggesting that its stock price is 331% less volatile than the broader market.

Zhengye Biotechnology's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Zhengye Biotechnology	N/A	N/A	N/A

Zhengye Biotechnology has higher revenue and earnings than Anthem.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Zhengye Biotechnology	$116.36M	0.70	-$9.98M	N/A	N/A

Summary

Anthem and Zhengye Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Zhengye Biotechnology (NASDAQ:ZYBT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Zhengye Biotechnology has a beta of -2.31, suggesting that its share price is 331% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

Zentalis Pharmaceuticals has a consensus price target of $7.50, indicating a potential upside of 184.09%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zhengye Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Zhengye Biotechnology has higher revenue and earnings than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.70	-$9.98M	N/A	N/A
Zentalis Pharmaceuticals	$67.43M	2.81	-$137.06M	-$1.95	N/A

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 6 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.67 beat Zentalis Pharmaceuticals' score of 0.33 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zentalis Pharmaceuticals beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

In the previous week, Zhengye Biotechnology had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Zhengye Biotechnology and 1 mentions for Cardiol Therapeutics. Zhengye Biotechnology's average media sentiment score of 0.67 beat Cardiol Therapeutics' score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Zhengye Biotechnology	Positive

12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zhengye Biotechnology's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Zhengye Biotechnology	N/A	N/A	N/A

Cardiol Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.31, indicating that its stock price is 331% less volatile than the broader market.

Zhengye Biotechnology has higher revenue and earnings than Cardiol Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Zhengye Biotechnology	$116.36M	0.70	-$9.98M	N/A	N/A

Cardiol Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 713.01%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cardiol Therapeutics and Zhengye Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Alpha Cognition?

Zhengye Biotechnology (NASDAQ:ZYBT) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Zhengye Biotechnology has higher revenue and earnings than Alpha Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.70	-$9.98M	N/A	N/A
Alpha Cognition	$15.26M	12.90	-$20.67M	-$1.10	N/A

In the previous week, Zhengye Biotechnology had 1 more articles in the media than Alpha Cognition. MarketBeat recorded 6 mentions for Zhengye Biotechnology and 5 mentions for Alpha Cognition. Zhengye Biotechnology's average media sentiment score of 0.67 beat Alpha Cognition's score of 0.59 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has a consensus price target of $18.00, indicating a potential upside of 99.12%. Given Alpha Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Alpha Cognition is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Zhengye Biotechnology has a beta of -2.31, meaning that its stock price is 331% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

Zhengye Biotechnology has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Zhengye Biotechnology's return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Alpha Cognition	-153.61%	-54.60%	-43.47%

Summary

Zhengye Biotechnology beats Alpha Cognition on 7 of the 12 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.50M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	N/A	797.58	274.15	26.16
Price / Sales	0.70	939.82	635.98	113.06
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.86	10.71	11.21	6.34
Net Income	-$9.98M	$2.84B	$3.50B	$381.90M
7 Day Performance	39.52%	-0.93%	-0.90%	-1.41%
1 Month Performance	8.81%	-4.91%	-4.44%	-3.48%
1 Year Performance	-36.86%	-4.13%	6.96%	1.16%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	0.8936 of 5 stars	$1.73 +50.4%	N/A	-36.4%	$54.50M	$116.36M	N/A	269	News Coverage Gap Up High Trading Volume
SLGL Sol-Gel Technologies	3.5434 of 5 stars	$73.00 -1.7%	$197.50 +170.5%	+81.0%	$208.72M	$19.39M	N/A	28	News Coverage Analyst Forecast Analyst Revision
ANTX Anthem	1.7204 of 5 stars	$5.62 +5.6%	$9.00 +60.1%	+254.8%	$200.76M	N/A	N/A	N/A	High Trading Volume
ZNTL Zentalis Pharmaceuticals	3.3745 of 5 stars	$2.61 -5.8%	$6.75 +158.6%	+45.9%	$198.53M	$67.43M	N/A	106	Gap Up
CRDL Cardiol Therapeutics	2.6202 of 5 stars	$1.56 -6.0%	$10.00 +541.0%	+12.8%	$197.42M	N/A	N/A	18

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. SLGL, ANTX, ZNTL, CRDL, and ACOG

How does Zhengye Biotechnology compare to Sol-Gel Technologies?

Summary

How does Zhengye Biotechnology compare to Anthem?

Summary

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Summary

How does Zhengye Biotechnology compare to Cardiol Therapeutics?

Summary

How does Zhengye Biotechnology compare to Alpha Cognition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. SLGL, ANTX, ZNTL, CRDL, and ACOG

How does Zhengye Biotechnology compare to Sol-Gel Technologies?

Does the media refer more to SLGL or ZYBT?

Which has more volatility & risk, SLGL or ZYBT?

Is SLGL or ZYBT more profitable?

Which has higher valuation & earnings, SLGL or ZYBT?

Do institutionals & insiders have more ownership in SLGL or ZYBT?

Do analysts prefer SLGL or ZYBT?

Summary

How does Zhengye Biotechnology compare to Anthem?

Do institutionals & insiders hold more shares of ANTX or ZYBT?

Does the media prefer ANTX or ZYBT?

Do analysts rate ANTX or ZYBT?

Which has more risk and volatility, ANTX or ZYBT?

Is ANTX or ZYBT more profitable?

Which has higher earnings and valuation, ANTX or ZYBT?

Summary

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Which has more risk and volatility, ZYBT or ZNTL?

Do analysts rate ZYBT or ZNTL?

Is ZYBT or ZNTL more profitable?

Which has stronger valuation & earnings, ZYBT or ZNTL?

Does the media favor ZYBT or ZNTL?

Summary

How does Zhengye Biotechnology compare to Cardiol Therapeutics?

Does the media refer more to CRDL or ZYBT?

Do insiders and institutionals have more ownership in CRDL or ZYBT?

Is CRDL or ZYBT more profitable?

Which has more volatility and risk, CRDL or ZYBT?

Which has preferable earnings & valuation, CRDL or ZYBT?

Do analysts prefer CRDL or ZYBT?

Summary

How does Zhengye Biotechnology compare to Alpha Cognition?

Which has better valuation & earnings, ZYBT or ACOG?

Does the media favor ZYBT or ACOG?

Do analysts prefer ZYBT or ACOG?

Which has more risk & volatility, ZYBT or ACOG?

Is ZYBT or ACOG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools